Tadalafil Tablet, Film Coated
Product Images NDC 72789-324

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 72789-324). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (72789324)

Label for tadalafil USP 5 mg film-coated tablets from PD-RX Pharmaceuticals, Inc. The label indicates a package size of 90 tablets with product NDC 72789-324-90. It includes usage instructions, lot number E23D50, and an expiration date of 01/2026. The label also features storage warnings and regulatory markings.*

FDA Label Image

Chemical Structure (Tadalafil 1)

Chemical structure diagram of tadalafil, showing its molecular framework including fused rings and functional groups, consistent with the active ingredient tadalafil in the product.*

FDA Label Image

Tadalafil-tablets-figure-1 (Tadalafil 2)

Four line graphs depicting the difference in blood pressure (Tadalafil minus placebo) over time in hours. The graphs show Standing Systolic BP, Standing Diastolic BP, Supine Systolic BP, and Supine Diastolic BP, each with data points and error bars from 0 to 96 hours.*

FDA Label Image

Tadalafil-tablets-figure-2 (Tadalafil 3)

Two line graphs showing the effect of tadalafil 20 mg combined with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic blood pressure over 24 hours. The top graph measures standing systolic BP (mmHg) and the bottom measures supine systolic BP (mmHg) post-dose. Time in hours is on the x-axis, with blood pressure change on the y-axis.*

FDA Label Image

Tadalafil-tablets-figure-3 (Tadalafil 4)

A line graph depicting the change in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo combined with doxazosin at 08:00 or 20:00. The graph compares four groups: 20 mg tadalafil at 08:00, placebo at 08:00, 20 mg tadalafil at 20:00, and placebo at 20:00, each with 8 mg daily doxazosin. Blood pressure changes fluctuate around baseline with varying trends among groups over time.*

FDA Label Image

Tadalafil-tablets-figure-4 (Tadalafil 5)

A pharmacokinetic line graph showing plasma tadalafil concentration (µg/L) over 120 hours. It compares three dosing conditions: a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg tadalafil following 5 consecutive days. Concentration peaks early and declines over time, with error bars indicating variability at each time point.*

FDA Label Image

Table 5 (Tadalafil 6)

A line graph comparing the change from baseline in IPSS total score over a 12-week treatment period between tadalafil 5 mg and placebo. The x-axis represents duration of treatment in weeks (0, 4, 8, 12) and the y-axis shows change from baseline with values ranging approximately from 0 to -6. Two lines represent tadalafil 5 mg and placebo, with tadalafil showing a greater decrease in score compared to placebo.*

FDA Label Image

Table 6 (Tadalafil 7)

A line graph comparing the change from baseline in IPSS total score over 12 weeks between Tadalafil 5 mg and placebo groups. The x-axis represents treatment duration in weeks (0, 1, 4, 8, 12) and the y-axis shows score change, with Tadalafil showing a greater decrease than placebo. Statistical significance is indicated for differences with p<0.01.*

FDA Label Image

Tadalafil-tablets-figure-7 (Tadalafil 8)

A line graph comparing the least squares mean change from baseline over weeks of therapy (0, 4, 12, 26 weeks) between Tadalafil/Finasteride and Placebo/Finasteride treatment groups. The y-axis represents changes from baseline with values decreasing downward. Tadalafil/Finasteride shows a greater decrease compared to Placebo/Finasteride at each time point, with statistical significance indicated by annotations (p<0.001 and p<0.05).*

FDA Label Image

Image 8 (Tadalafil 9)

A line graph depicting the change from baseline in IPSS total score over 12 weeks of treatment, comparing tadalafil 5 mg with placebo. The graph shows a greater decrease in score for tadalafil 5 mg, with time points at 0, 2, 4, 8, and 12 weeks. Statistically significant differences (p<0.01) are indicated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.